{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:50Z","timestamp":1792123790211,"version":"4.4.0"},"reference-count":29,"publisher":"Informa UK Limited","issue":"16","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/14796694.2025.2511564","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:12:01Z","timestamp":1749193921000},"page":"2077-2087","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis"],"prefix":"10.1080","volume":"21","author":[{"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Simpson","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Cho","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"Conlon","sequence":"additional","affiliation":[{"name":"GSK plc","place":["Reading, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1048"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0046"},{"key":"e_1_3_8_6_1","unstructured":"Incyte corporation. Jakafi (ruxolitinib). Prescribing information. 2021. Available from: https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf"},{"key":"e_1_3_8_7_1","unstructured":"Bristol Myers Squibb. Inrebic [prescribing information]. 2022. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf"},{"key":"e_1_3_8_8_1","unstructured":"GSK. Ojjaara [Prescribing information]. 2023. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_8_15_1","unstructured":"FDA application number 212327Orig1s000. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212327Orig1s000Approv.pdf"},{"key":"e_1_3_8_16_1","unstructured":"EMA inrebic assessment report. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/inrebic-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18207"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000562"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01822-X"},{"key":"e_1_3_8_21_1","unstructured":"CTI Biopharma Corp. Vonjo (pacritinib). Prescribing information. 2022."},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.591"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000954"},{"key":"e_1_3_8_28_1","volume-title":"Safety and tolerability of fedratinib, an oral inhibitor of janus kinase 2, in patients with intermediate-or high-risk myelofibrosis previously treated with ruxolitinib: results from the phase 3b FREEDOM trial","author":"Gupta V","year":"2021","unstructured":"Gupta V, Yacoub A, Verstovsek S, et al. Safety and tolerability of fedratinib, an oral inhibitor of janus kinase 2, in patients with intermediate-or high-risk myelofibrosis previously treated with ruxolitinib: results from the phase 3b FREEDOM trial. Atlanta (GA): ASH; 2021."},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00526-z"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282612"},{"key":"e_1_3_8_31_1","volume-title":"Clinical effectiveness and safety of momelotinib compared with continued ruxolitinib or best available therapy in patients with myelofibrosis who required red blood cell transfusions: subgroup analysis of the phase 3 SIMPLIFY-2 study","author":"Harrison C","year":"2023","unstructured":"Harrison C, Vannucchi A, Recher C, et al., editors. Clinical effectiveness and safety of momelotinib compared with continued ruxolitinib or best available therapy in patients with myelofibrosis who required red blood cell transfusions: subgroup analysis of the phase 3 SIMPLIFY-2 study. San Diego (CA): ASH; 2023."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2511564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:21:18Z","timestamp":1763043678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2511564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/14796694.2025.2511564"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2511564","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}